We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abingdon Health Plc | LSE:ABDX | London | Ordinary Share | GB00BLF79J41 | ORD 0.025P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.75 | 9.50 | 10.00 | 9.75 | 9.75 | 9.75 | 102,989 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 4.05M | -3.45M | -0.0284 | -3.43 | 11.87M |
TIDMABDX
RNS Number : 4427U
Abingdon Health PLC
02 December 2021
2 December 2021
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Launch of Open Offer, Posting of Circular, Notice of General Meeting
York, U.K. 2 December 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, is pleased to announce that further to the Company's announcement on 1 December 2021 (the "Proposed Fundraising"), the Company will today post a Circular to Qualifying Shareholders regarding the Open Offer of up to 4,000,000 Open Offer Shares in the Company at the Issue Price of 25 pence per Open Offer Share to raise up to approximately GBP1 million (before expenses).
Pursuant to the Open Offer, Qualifying Shareholders will be given the opportunity to subscribe for:
1 Open Offer Share for every 23.9247785 Existing Ordinary Shares
held by each Qualifying Shareholder on the Record Date.
Any Open Offer Shares not subscribed for by Qualifying Shareholders will be available to Qualifying Shareholders under the Excess Application Facility and as such, Qualifying Shareholders seeking to limit their dilution from the Placing, the Subscription and the Primary Bid Offer can also request additional Open Offer Shares ("Excess Shares") under the Excess Application Facility. The Open Offer is not being underwritten.
The Open Offer is conditional upon, among other matters, the Second Placing becoming or being declared unconditional in all respects and not being terminated before Second Admission.
Posting of Circular
Further details regarding the Open Offer are available in the Circular, which has been posted today to Qualifying Shareholders, along with the Application Form (where applicable). The Circular will also be made available on the Company's website: www.abingdonhealth.com/investors/
Notice of General Meeting
A notice convening a General Meeting of the Company is set out at the end of the Circular. The General Meeting has been convened for 10.30 a.m. on 20 December 2021 at the offices of Abingdon Health plc at York Biotech Campus, Sand Hutton, York, YO41 1LZ.
Capitalised terms used in this announcement have the meanings given to them in the Circular, unless the context provides otherwise.
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/ Chris Yates, Chief Executive Officer Via Walbrook PR Melanie Ross , Chief Financial Officer Christopher Hand, Non-Executive Chairman Singer Capital Markets Securities Limited Tel: +44 (0)20 7496 3000 (Sole Bookrunner and Broker) Singer Capital Markets Advisory LLP (Nominated Adviser) Shaun Dobson, Peter Steel, Alex Bond (Corporate Finance) Tom Salvesen (Corporate Broking) Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com Paul McManus / Phillip Mob: +44 (0)7980 541 893 / +44 (0)77867 Marriage 984 082 Alice Woodings Mob: +44 (0)7407 804 654
Expected timetable of principal events:
2021 Record Date for entitlement under the Open Offer 30 November Announcement of the Fundraising 7.00 a.m. on 1 December Announcement of the results of the Placing, the 1 December Subscription and the PrimaryBid Offer Publication and posting of the Circular, Notice 2 December of General Meeting, Form of Proxy and, to Qualifying Non-Crest Shareholders, the Application Form Ex-Entitlement Date of the Open Offer 2 December Open Offer Entitlements and Excess Open Offer Entitlements 3 December credited to stock accounts in CREST of Qualifying CREST Shareholders Admission of the First Placing Shares to trading 8 a.m. on 3 December on AIM and commencement of dealings Where applicable, expected date for CREST accounts 3 December to be credited in respect of First Placing Shares in uncertificated form Latest recommended time and date for requested withdrawal 4.30 p.m. on 13 of Open Offer Entitlements December Latest time and date for depositing Open Offer Entitlements 3.00 p.m. on 14 in CREST December Latest time and date for splitting of Application 3.00 p.m. on 15 Forms under the Open Offer December Latest time and date for receipt of Forms of Proxy 10.30 a.m. on and CREST voting instructions 16 December Latest time and date for receipt of Application 11.00 a.m. on Forms and payment in full under the Open Offer and 17 December settlement of relevant CREST instructions (as appropriate) Where applicable, expected date for dispatch of 17 December definitive share certificates for First Placing Shares in certificated form General Meeting 10.30 a.m. on 20 December Results of the General Meeting and the Open Offer 20 December announced Admission of the Second Admission Shares to trading 8 a.m. on 21 December on AIM and commencement of dealings Where applicable, expected date for CREST accounts 21 December to be credited in respect of Second Admission Shares in uncertificated form Where applicable, expected date for dispatch of 6 January 2022 definitive share certificates for Second Admission Shares in certificated form
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCUPGGCPUPGGMP
(END) Dow Jones Newswires
December 02, 2021 12:43 ET (17:43 GMT)
1 Year Abingdon Health Chart |
1 Month Abingdon Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions